Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Surg Oncol ; 28(3): 1642-1653, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32944786

ABSTRACT

BACKGROUND: Extracapsular spread (ECS) is recognized to be a high-risk factor in melanoma patients with macrometastatic (N+) nodal disease; however, ECS risk in sentinel lymph node (SLN) biopsy, micrometastatic stage III disease is ambiguous. OBJECTIVE: The aim of this study was to examine ECS incidence and its prognostic significance. METHODS: A two-center, retrospective analysis of all patients with micro/macrometastatic lymphadenopathy undergoing nodal surgery from 2008 to 2014 was performed. Patient demographics, tumor characteristics, nodal ECS status, and patient outcomes were collected. RESULTS: Overall, 515 patients with nodal disease were identified (males/females = 277/238); median age was 63 years (range 17-94). There was an increased frequency of ECS disease in N+ disease compared with SLN+ disease (52.4% vs. 16.2%; p < 0.0001). The absolute disease-specific survival (DSS) difference for SLN+ patients was approximately 30% at 10 years (66.2% vs. 37.2%; p < 0.0001), and the prognosis of SLN+/ECS+ patients was identical to N+/ECS- patients. Multivariate analysis demonstrated that ECS status was an independent prognostic indicator for DSS (hazard ratio 2.47, 95% confidence interval 1.87-3.26; p < 0.0001) in patients with SLN+ disease. There were significant differences in nodal burden according to ECS status between the SLN+ and N+ subgroups suggestive of differing biology in ECS+ tumors. CONCLUSION: We found that ECS is a significant DSS, progression-free survival, and overall survival indicator in SLN+ and N+ disease. We demonstrated that ECS upstages stage III disease, similar to ulceration in primary melanoma (stage I/II disease). A simplified staging system substituting ECS for N stage accurately stages patients according to prognosis.


Subject(s)
Lymphadenopathy , Melanoma , Skin Neoplasms , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Lymphatic Metastasis , Male , Melanoma/pathology , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Sentinel Lymph Node Biopsy , Skin Neoplasms/pathology , Survival Rate , Young Adult
2.
Cancer Immunol Immunother ; 69(4): 559-568, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31974724

ABSTRACT

OBJECTIVES: The neutrophil-lymphocyte ratio (NLR) is an inflammatory biomarker which is useful in cancer prognostication. We aimed to investigate the differences in baseline NLR between patients with localised and metastatic cutaneous melanoma and how this biomarker changed over time with the recurrence of disease. METHODS: This multicentre cohort study describes patients treated for Stage I-III cutaneous melanoma over 10 years. The baseline NLR was measured immediately prior to surgery and again at the time of discharge or disease recurrence. The odds ratios (OR) for sentinel node involvement are estimated using mixed-effects logistic regression. The risk of recurrence is estimated using multivariable Cox regression. RESULTS: Overall 1489 individuals were included. The mean baseline NLR was higher in patients with palpable nodal disease compared to those with microscopic nodal or localised disease (2.8 versus 2.4 and 2.3, respectively; p < 0.001). A baseline NLR ≥ 2.3 was associated with 30% higher odds of microscopic metastatic melanoma in the sentinel lymph node [adjusted OR 1.3 (95% CI 1.3, 1.3)]. Following surgery, 253 patients (18.7%) developed recurrent melanoma during surveillance although there was no statistically significant association between the baseline NLR and the risk of recurrence [adjusted HR 0.9 (0.7, 1.1)]. CONCLUSION: The NLR is associated with the volume of melanoma at presentation and may predict occult sentinel lymph metastases. Further prospective work is required to investigate how NLR may be modelled against other clinicopathological variables to predict outcomes and to understand the temporal changes in NLR following surgery for melanoma.


Subject(s)
Lymphocytes/pathology , Melanoma/blood , Neutrophils/pathology , Skin Neoplasms/blood , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Kaplan-Meier Estimate , Leukocyte Count , Lymphatic Metastasis , Male , Melanoma/pathology , Melanoma/surgery , Middle Aged , Neoplasm Staging , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Melanoma, Cutaneous Malignant
3.
Mol Ther ; 27(6): 1139-1152, 2019 06 05.
Article in English | MEDLINE | ID: mdl-31053413

ABSTRACT

A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and is now licensed for clinical use in advanced melanoma. To date, limited data are available regarding the mechanisms of human anti-tumor immune priming, an improved understanding of which could inform the development of future combination strategies with improved efficacy. This study addressed direct oncolysis and innate and adaptive human immune-mediated effects of a closely related HSV encoding GM-CSF (HSVGM-CSF) alone and in combination with histone deacetylase inhibition. We found that HSVGM-CSF supported activation of anti-melanoma immunity via monocyte-mediated type I interferon production, which activates NK cells, and viral maturation of immature dendritic cells (iDCs) into potent antigen-presenting cells for cytotoxic T lymphocyte (CTL) priming. Addition of the histone deacetylase inhibitor valproic acid (VPA) to HSVGM-CSF treatment of tumor cells increased viral replication, viral GM-CSF production, and oncolysis and augmented the development of anti-tumor immunity. Mechanistically, VPA increased expression of activating ligands for NK cell recognition and induced expression of tumor-associated antigens, supporting innate NK cell killing and CTL priming. These data support the clinical combination of talimogene laherparepvec with histone deacetylase inhibition to enhance oncolysis and anti-tumor immunity.


Subject(s)
Histone Deacetylase Inhibitors/therapeutic use , Melanoma/therapy , Oncolytic Virotherapy/methods , Oncolytic Viruses/metabolism , Simplexvirus/immunology , Skin Neoplasms/therapy , Valproic Acid/therapeutic use , Antigens, Neoplasm/drug effects , Antigens, Neoplasm/metabolism , Antineoplastic Agents, Immunological/therapeutic use , Biological Products/therapeutic use , Cell Survival/genetics , Dendritic Cells/immunology , Drug Therapy, Combination , Genetic Vectors , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Herpesvirus 1, Human , Humans , Interferon Type I/metabolism , Killer Cells, Natural/immunology , MCF-7 Cells , Melanoma/pathology , Oncolytic Viruses/genetics , Simplexvirus/genetics , Skin Neoplasms/pathology , T-Lymphocytes, Cytotoxic/immunology
4.
Ann Surg Oncol ; 25(11): 3341-3349, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30066226

ABSTRACT

BACKGROUND: In the peripheral blood, the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are associated with adverse outcomes in numerous cancers, but the evidence is limited in relation to melanoma. This study sought to investigate the association between these biomarkers and survival in Stages I-III cutaneous melanoma. METHODS: This multicenter cohort study investigated a consecutive series of patients who underwent wide excision of biopsy-proven cutaneous melanoma and sentinel lymph node biopsy during a 10-year period. The baseline NLR and PLR were calculated immediately before sentinel lymph node biopsy. Adjusted hazard ratios (HRs) for overall and melanoma-specific survival were generated. RESULTS: Overall, 1351 patients were included in the study. During surveillance, 184 of these patients died (14%), with 141 of the deaths (77%) attributable to melanoma. Worse overall survival was associated with a baseline NLR lower than 2.5 [HR 2.2; 95% confidence interval (CI) 2.0 to 2.3; p < 0.001] and a baseline PLR lower than 100 (HR 1.8; 95% CI 1.7 to 1.8; p < 0.001). Melanoma-specific survival also was worse, with a baseline NLR lower than 2.5 (HR 1.9; 95% CI 1.6 to 2.2; p < 0.001) and a baseline PLR lower than 100 (HR 1.9; 95% CI 1.7 to 2.2; p < 0.001). The 5-year survival for patients with sentinel lymph node metastases and a low NLR and PLR was approximately 50%. CONCLUSION: This study provides important new data on biomarkers in early-stage melanoma, which contrast with biomarker profiles in advanced disease. These biomarkers may represent the host inflammatory response to melanoma and therefore could help select patients for adjuvant therapy and enhanced surveillance.


Subject(s)
Biomarkers, Tumor/analysis , Blood Platelets/pathology , Lymphocytes/pathology , Melanoma/mortality , Neoplasm Recurrence, Local/mortality , Neutrophils/pathology , Skin Neoplasms/mortality , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Melanoma/pathology , Melanoma/surgery , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Prognosis , Prospective Studies , Retrospective Studies , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Survival Rate
6.
Br J Plast Surg ; 57(2): 97-104, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15037163

ABSTRACT

Sentinel node biopsy has become an integral part of the management of malignant melanoma. Here, the authors describe the technique that is used at the St George's Hospital Melanoma Unit. Results obtained over the past 5 years on a cohort of patients are presented. Three hundred and forty seven patients were entered in the study. Population demographics were analysed for both the primary melanoma and for sentinel node positive status. Histological features of the primary, particularly regression were noted and, in addition to metastatic disease, the presence of capsular naevus cells within the node also recorded. Complications associated with the procedure have been presented along with the specificity and sensitivity of the technique. The relative influence of both Breslow thickness and sentinel node positivity were analysed statistically and Kaplan-Meier survival curves produced for the cohort as a whole. This confirmed the accuracy of sentinel node biopsy and its role as a prognostic indicator.


Subject(s)
Melanoma/pathology , Sentinel Lymph Node Biopsy/methods , Skin Neoplasms/secondary , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Lymphatic Metastasis , Male , Melanoma/mortality , Melanoma/surgery , Middle Aged , Prognosis , Retrospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/surgery , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...